BPC-157 and TB-500: Research Update for Medical Practices

BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4) are two of the most extensively researched peptides in the RUO (Research Use Only) catalog. For medical practices and research laboratories working with these compounds, staying current on the research landscape is important.

This post summarizes the current research on BPC-157 and TB-500 and what it means for practices that work with these compounds.

Important reminder: BPC-157 and TB-500 are Research Use Only compounds. They are not FDA-approved for therapeutic use and cannot be administered to humans outside of an IRB-approved research protocol.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in gastric juice. It was first isolated and characterized in the 1990s by researchers studying gastric cytoprotection.

BPC-157 has been studied for multiple mechanisms:

Angiogenesis: BPC-157 appears to promote the formation of new blood vessels (angiogenesis) through upregulation of VEGF (vascular endothelial growth factor). This mechanism is thought to underlie many of its tissue repair effects.

Nitric oxide system: BPC-157 modulates the nitric oxide system, which plays a role in vascular tone, inflammation, and tissue repair.

Growth factor modulation: BPC-157 appears to modulate multiple growth factors involved in tissue repair, including EGF (epidermal growth factor) and FGF (fibroblast growth factor).

Tendon and ligament repair: BPC-157 has been extensively studied in rodent models of tendon and ligament injury. Multiple studies have shown accelerated healing with BPC-157 treatment.

Gut protection: BPC-157 has shown protective effects in rodent models of inflammatory bowel disease, NSAID-induced gut damage, and other GI conditions.

2024 study in Journal of Orthopaedic Research: Examined BPC-157 in a rodent model of rotator cuff injury. BPC-157 treatment significantly accelerated tendon healing compared to controls, with improved tensile strength at 4 and 8 weeks.

2025 study in Inflammatory Bowel Diseases: Examined BPC-157 in a rodent model of colitis. BPC-157 reduced inflammatory markers and improved mucosal healing compared to controls.

2025 review in Peptides: Comprehensive review of BPC-157 research concluded that the compound shows consistent tissue repair effects in animal models across multiple tissue types, but noted the absence of human clinical trial data.

The most significant limitation of BPC-157 research is the absence of human clinical trial data. All published research is from animal models (primarily rodents). While the animal data is consistent and compelling, the translation to humans is not established.

This is why BPC-157 remains an RUO compound — the evidence base, while promising, does not yet support FDA approval for therapeutic use.

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring peptide found in virtually all human and animal cells. Thymosin Beta-4 was first isolated from thymus tissue in the 1960s.

Actin regulation: Thymosin Beta-4 is primarily known as an actin-sequestering protein. It binds to G-actin (monomeric actin) and regulates actin polymerization, which is critical for cell migration and tissue repair.

Cell migration: By regulating actin dynamics, Thymosin Beta-4 promotes cell migration — a key step in wound healing and tissue repair.

Anti-inflammatory effects: Thymosin Beta-4 has anti-inflammatory properties, reducing inflammatory cytokine production.

Cardiac repair: Thymosin Beta-4 has been studied for cardiac repair following myocardial infarction. It promotes cardiomyocyte survival and angiogenesis in the injured heart.

Neurological effects: Thymosin Beta-4 has been studied for neuroprotection and neural repair.

2024 study in Circulation Research: Examined Thymosin Beta-4 in a porcine model of myocardial infarction. Treatment improved cardiac function and reduced infarct size compared to controls.

2025 study in Journal of Neuroinflammation: Examined Thymosin Beta-4 in a rodent model of traumatic brain injury. Treatment reduced neuroinflammation and improved functional outcomes.

2025 clinical trial (Phase 2): A Phase 2 trial of Thymosin Beta-4 in patients with dry eye disease showed improvement in corneal healing compared to placebo. This represents one of the few human clinical trials of a Thymosin Beta-4-related compound.

Unlike BPC-157, Thymosin Beta-4 has some human clinical trial data — primarily in ophthalmology (dry eye disease) and wound healing. However, the data is limited, and no Thymosin Beta-4 product is FDA-approved for systemic use.

We supply both BPC-157 and TB-500 as RUO peptides with ≥99% purity, COA from independent laboratory, and proper RUO labeling.

Contact us about RUO peptide availability →

BPC-157 and TB-500 are Research Use Only compounds. They are not FDA-approved for therapeutic use and cannot be administered to humans outside of an IRB-approved research protocol. For licensed research facilities only.